Live Breaking News & Updates on Zydus

Stay informed with the latest breaking news from Zydus on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Zydus and stay connected to the pulse of your community

cdmo: Foram Parekh on what to bet on in pharma pack

Foram Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus's earnings improvement, Sun Pharma's specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy's.

Dadra , Dadra-and-nagar-haveli , India , Lucknow , Uttar-pradesh , China , Chinese , Sun-pharma , Foram-parekh , Offering-college , Cipla , Indian-school-of-business

Zydus Wellness stocks: Buy Zydus Wellness, target price Rs 1910: Anand Rathi

Zydus Wellness Ltd. key Products/Revenue Segments include Personal Care and Other Operating Revenue for the year ending 31-Mar-2023.

Economic-times , Zydus-wellness-stocks , Markets , Market-news , Sensex , Nifty , Zydus-wellness , Zydus , Zydus-ltd , Zydus-wellness-ltd , Zydus-wellness-ltd-

Zydus aims to launch first new drug in US by early 2026

Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease."

United-states , India , Ahmedabad , Gujarat , Zydus-lifesciences , Sun-pharma-cipla , Sharvil-patel , Novo-nordisk , Gilead-sciences , Reuters , Managing-director-sharvil-patel , Primary-biliary-cholangitis

Zydus gets USFDA nod for generic medication for postherpetic neuralgia

The drug maker is the first company to receive final approval for generic Gabapentin tablets (300 mg and 600 mg), it added. The product will be launched immediately in the US market, the drug firm stated.

Zydus-lifesciences , Drug-administration , Zydus ,

Zydus gets USFDA nod for generic medication

Zydus Lifesciences announced that it has obtained approval from the USFDA to sell a generic medication for the treatment of postherpetic neuralgia. The company has received the final nod from the US Food and Drug Administration (USFDA) to produce and distribute Gabapentin tablets in strengths of 300 mg and 600 mg, as stated in a regulatory filing by Zydus Lifesciences.

New-delhi , Delhi , India , Zydus-lifesciences , Drug-administration , Zydus , Usfda , Generic-medication , Gabapentin-tablets , Postherpetic-neuralgia ,

Zydus Receives USFDA Approval for Generic Medication | India News

India News: Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) to market a generic medication to manage postherpetic neuralgia. Read more.

Zydus-lifesciences , Drug-administration , India , Ndia-news , Ndia-news-today , Oday-news , Oogle-news , Reaking-news , Zydus , Usfda , Generic-medication , Gabapentin-tablets

Zydus Group to invest Rs 5,000 cr in Gujarat

Zydus Group plans to invest Rs 5,000 crore in Gujarat, including biotechnology products and hospitals. Memoranda of Understanding (MoUs) have been signed. Nayara Energy will expand its refinery at Vadinar and increase its retail network. Torrent Group will invest nearly Rs 48,000 crore in energy generation and distribution, including solar and hydel plants. Welspun Group will invest Rs 40,000 crore in the state over the next five years.

Gandhinagar , Gujarat , India , Narendra-modi , Amit-shah , Pankaj-patel , Balkrishan-goenka , Prasad-panicker , Union-home , Zydus-group-on , Welspun-group , Nayara-energy

Zydus Life subsidiary gets Income Tax demand of Rs 280 cr

ZHL does not expect the said intimation to have any material financial impact as the above-mentioned adjustments are not sustainable in law and are wholly defendable on the facts of the case, the company added

Cpc-income-tax-department , Income-tax-department , Zydus-healthcare , Zydus-life , Zydus-healthcare-limited , Income-tax , Healthcare-limited , Moneycontrol-selects , Rectification-application , Jurisdictional-assessing-officer , Zydus

Stocks in news: PB Fintech, ZEE, PVR Inox, KFin Tech, Mazagon Dock

Zee Entertainment has sent a letter to Sony Group Corporation requesting an extension of the cutoff to complete the merger.

Virginia , United-states , Japan , India , Japanese , Softbank-group , Sony-group-corporation , Granules-india , General-atlantic , Private-equity , Actimed-therapeutics

stocks to buy: F&O stocks to buy today: IGL, IEX among top 9 trading ideas for 8 December 2023

Positive setup was seen in stocks like Tata Power, IEX, Container Corporation, India Cement, MGL, MCX, Zydus Life, LIC Housing Finance, BEL, Voltas, BHEL, etc.

India , Pritesh-mehta , Chandan-taparia , Kunal-bothra , Nooresh-merani , Container-corporation , Derivatives-at-motilal-oswal-financial-services , Tata-power , India-cement , Zydus-life , Motilal-oswal-financial-services-limited , Lead-technical-analyst